Gerrit H Gielen

List of Publications by Year
in descending order

20 papers	510 citations	11 h-index	20 g-index
22 all docs	22 docs citations	22 times ranked	1132 citing authors

840776

752698

#	ARTICLE	IF	CITATIONS
1	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology, 2018, 20, 123-131.	1.2	184
2	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine, 2020, 52, 102647.	6.1	38
3	Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Cell Death and Disease, 2020, 11, 673.	6.3	36
4	The ERICA Score: An MR Imaging–based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology, 2018, 288, 226-333.	7.3	33
5	Intravoxel incoherent motion MRI in the brain: Impact of the fitting model on perfusion fraction and lesion differentiability. Journal of Magnetic Resonance Imaging, 2017, 46, 1187-1199.	3.4	32
6	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine, 2020, 59, 102962.	6.1	31
7	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
8	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunology, Immunotherapy, 2021, 70, 1781-1788.	4.2	22
9	Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Clinical Cancer Research, 2021, 27, 3704-3713.	7.0	19
10	<i>PDGRFB</i> mutation–associated myofibromatosis: Response to targeted therapy with imatinib. American Journal of Medical Genetics, Part A, 2019, 179, 1895-1897.	1.2	14
11	A suggestion to introduce the diagnosis of "diffuse midline glioma of the pons, H3 K27 wildtype (WHO) Tj ETQq1 1 0.784314 rgB	7.7	13
12	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. Neuroradiology, 2017, 59, 1223-1231.	2.2	12
13	DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study. Clinical Neuroradiology, 2021, 31, 1049-1058.	1.9	10
14	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma. Clinical Neuroradiology, 2022, 32, 249-258.	1.9	8
15	Meningioma assessment: Kinetic parameters in dynamic contrast-enhanced MRI appear independent from microvascular anatomy and VEGF expression. Journal of Neuroradiology, 2018, 45, 242-248.	1.1	7
16	Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. Oncotarget, 0, 7, 41898-41912.	1.8	7
17	Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. Journal of Neuro-Oncology, 2017, 133, 155-163.	2.9	6
18	Challenging Implications of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids Syndrome with an Atypical Presentation: Report of Two Cases. World Neurosurgery, 2020, 143, 507-512.e1.	1.3	5

#	Article	IF	Citations
19	Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. European Journal of Cancer, 2017, 81, 1-8.	2.8	4
20	Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. Journal of Clinical Neuroscience, 2018, 53, 255-258.	1.5	1